Get 25% discount on our yearly plans! Subscribe now

Key Metrics
Market Cap
Total Shares Outstanding
Book Value
PE Ratio
PS Ratio
PB Ratio
Forward PE Ratio
ROIC
Return on Aseets
Return on Equity
Dividend
Dividend Yield
Balancesheet Metrics
Total Assets
Total Liability
Assets-to-Libability Ratio
Total Current Assets
Total Current Liability
Current Ratio
Quick Ratio
Debt to Equity Ratio
Income Statement Metrics
Net Income
EPS
EBITA
Gross Profit
Gross Profit Margin
Operating Margin
Net Profit Margin
Price Metrics
5 Days MA
10 Days MA
20 Days MA
50 Days MA
200 Days MA
52 Weeks High
52 Weeks low
All Time High
RSI
MACD
Share Stats
Shares Float
Shares Short
% Short
% Insider
% Institutions
News
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023Fortress Biotech, Inc. MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today ann...

FBIO FBIOP | finance.yahoo | about 2 years ago | Neutral
Mustang Bio to Participate in Two August 2023 Investor ConferencesMustang Bio, Inc. WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare...

FBIO FBIOP MBIO | finance.yahoo | about 2 years ago | Neutral
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023Journey Medical Corporation Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET Company and Neal Bhatia, MD, Director of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA and Investigator in over 75 clinica...

DERM FBIO FBIOP | finance.yahoo | about 2 years ago | Neutral
Insiders Re-Evaluate Their US$3.4m Stock Purchase As Fortress Biotech Falls To US$77mInsiders who acquired US$3.4m worth of Fortress Biotech, Inc.'s (NASDAQ:FBIO) stock at an average price of US$0.83 in the past 12 months may be dismayed by the recent 12% price decline. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent lo...

FBIO FBIOP | finance.yahoo | about 2 years ago | Neutral
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical StudyAvenue Therapeutics -A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024 MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapi...

ATXI FBIO FBIOP | finance.yahoo | about 2 years ago | Neutral
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) BiosciencesMustang Bio, Inc. Transaction and reduction in operating expenses enhance Mustang’s cash position WORCESTER, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical bre...

FBIO FBIOP MBIO | finance.yahoo | about 2 years ago | Neutral
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-MarketCheckpoint Therapeutics, Inc WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an a...

CKPT FBIO FBIOP | finance.yahoo | about 2 years ago | Neutral
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)Avenue Therapeutics Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases...

ATXI FBIO FBIOP | finance.yahoo | about 2 years ago | Neutral
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell CarcinomaCheckpoint Therapeutics, Inc 55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety profile Biologics License Application currently under r...

CKPT FBIO FBIOP | finance.yahoo | about 2 years ago | Neutral
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV TramadolAvenue Therapeutics MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it has r...

ATXI FBIO FBIOP | finance.yahoo | about 2 years ago | Neutral
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;Totals
Totals-